References
- Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–81.
- Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48: 964–70.
- van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692–706.
- De Arriba JJ, Nerin C, Garcia E, Gomez-Aldaravi L, Vila B. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol 2003;14:962.
- van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001;358:1421–3.
- Miyazawa K, Nishimaki J, Katagiri T, Sashida G, Shoji N, Kawakubo K, et al. Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: Is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?Int J Hematol 2003;77: 93–5.
- Neely JL, Rosen C. Vocal fold hemorrhage associated with coumadin therapy in an opera singer. J Voice 2000;14: 272–7.
- Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002;99:3530–9.
- Postma GN, Courey MS, Ossoff RH. Microvascular lesions of the true vocal fold. Ann Otol Rhinol Laryngol 1998;107: 472–6.
- Samimi-Fard S, Garcia-Gonzalez M, Dominguez-Rodriguez A. Vocal cord haematoma after tenecteplase thrombolysis. Acta Otolaryngol 2006;126:884–5.